Heart Failure Clinical Trial
— RATEOfficial title:
Reduced Anticoagulation Targets in ECLS (RATE)
The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.
Status | Recruiting |
Enrollment | 330 |
Est. completion date | March 1, 2024 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ECMO treatment during the study period in one of the participating centers - Age above 18 years - Written informed consent Exclusion Criteria: - Patients in whom the ECMO is only used to bridge a procedure - Vital indication for robust anticoagulation (e.g. mechanic valve, pulmonary embolism) - History of heparin induced thrombocytopenia |
Country | Name | City | State |
---|---|---|---|
Netherlands | Amsterdam UMC, location AMC | Amsterdam | Noord-Holland |
Netherlands | OLVG, location East | Amsterdam | Noord-Holland |
Netherlands | University Medical Center Groningen | Groningen | |
Netherlands | Leids Universitair Medisch Centrum | Leiden | Zuid-Holland |
Netherlands | Maastricht Universitair Medisch Centrum+ | Maastricht | Limburg |
Netherlands | St. Antonius Ziekenhuis | Nieuwegein | Utrecht |
Netherlands | Radboud UMC | Nijmegen | Gelderland |
Netherlands | Erasmus MC | Rotterdam | Zuid-Holland |
Netherlands | Isala Clinics | Zwolle | Overijssel |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Isala, Leiden University Medical Center, OLVG, Radboud University, St. Antonius Hospital, ZonMw: The Netherlands Organisation for Health Research and Development |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hemorrhagic complications | Severe hemorrhagic complications will be registered according to the Extracorporeal Life Support Organization (ELSO) definitions for major bleeding and is defined as clinically overt bleeding with a decrease in hemoglobin of at least 1,24 mmol/L (2 g/dl)/24 hours, or a transfusion requirement of = 3 EH RBC over that same time period. Bleeding that is retroperitoneal, pulmonary or involves the central nervous system, or bleeding that requires surgical intervention is also considered major bleeding. | Through ECLS completion, an average of 14 days | |
Primary | Severe thromboembolic complications | Severe thromboembolic complication defined as ischemic stroke, limb ischemia, or acute pump failure | Through ECLS completion, an average of 14 days | |
Primary | Mortality | Mortality at 6 months | 6 months after ECLS | |
Secondary | Number of blood transfusions | Number of blood transfusions during ECLS | Through ECLS completion, an average of 14 days | |
Secondary | Quality of life at 6 months | Quality of life (HR-QoL) measured 6 months after decannulation from ECMO | 6 months after ECLS | |
Secondary | Exchange of the membrane oxygenator | Number of echanges of the membrane oxygenator during ECLS | Through ECLS completion, an average of 14 days | |
Secondary | Vessel thrombosis after ECLS removal | Vessel thrombosis after ECLS removal detected by echography | After ECLS completion, an average of 14 days | |
Secondary | Cost- effectiveness | Cost- effectiveness will be based on reduced costs of blood transfusions and interventions for bleeding (e.g. surgery, interventional radiology) as well as improved outcome. All medical cost items expected to be affected by the ECMO therapy will be measured and valued according to the Dutch standard guidelines for economic evaluations, e.g. blood transfusion, number of ECMO replacements, surgery, and hospital length of stay. | 6 months after ECLS | |
Secondary | Pulmonary embolism | The occurrence of Pulmonary embolism during ECLS | Through ECLS completion, an average of 14 days | |
Secondary | All thromboembolic complications combined | The occurrence of all thromboembolic complications combined during ECLS | Through ECLS completion, an average of 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|